Cargando…
Janus kinase inhibitors for the therapy of atopic dermatitis
The JAK-STAT pathway is involved in the signaling of multiple cytokines driving cutaneous inflammation in atopic dermatitis (AD). Janus kinase (JAK) inhibitors target individual receptor-associated kinases, thereby preventing the mediation of inflammatory signals. Several JAK inhibitors with varying...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439108/ https://www.ncbi.nlm.nih.gov/pubmed/34532638 http://dx.doi.org/10.5414/ALX02272E |
_version_ | 1783752474490830848 |
---|---|
author | Traidl, Stephan Freimooser, Sina Werfel, Thomas |
author_facet | Traidl, Stephan Freimooser, Sina Werfel, Thomas |
author_sort | Traidl, Stephan |
collection | PubMed |
description | The JAK-STAT pathway is involved in the signaling of multiple cytokines driving cutaneous inflammation in atopic dermatitis (AD). Janus kinase (JAK) inhibitors target individual receptor-associated kinases, thereby preventing the mediation of inflammatory signals. Several JAK inhibitors with varying mechanism of action, potency, and safety represent potential therapeutic options for AD in both topical and systemic application. The JAK1/2 selective JAK inhibitor baricitinib was the first substance from this class of drugs approved by the EMA for the systemic oral treatment of AD. The clinical development program of the JAK1 selective inhibitors upadacitinib and abrocitinib is finalized with positive results for AD. The PAN-JAK inhibitor delgocitinib was the first substance being approved for the treatment of AD (in Japan). This review article covers the rising data on investigational and approved JAK inhibitors in the context of the treatment of AD. |
format | Online Article Text |
id | pubmed-8439108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dustri-Verlag Dr. Karl Feistle |
record_format | MEDLINE/PubMed |
spelling | pubmed-84391082021-09-15 Janus kinase inhibitors for the therapy of atopic dermatitis Traidl, Stephan Freimooser, Sina Werfel, Thomas Allergol Select Review Article The JAK-STAT pathway is involved in the signaling of multiple cytokines driving cutaneous inflammation in atopic dermatitis (AD). Janus kinase (JAK) inhibitors target individual receptor-associated kinases, thereby preventing the mediation of inflammatory signals. Several JAK inhibitors with varying mechanism of action, potency, and safety represent potential therapeutic options for AD in both topical and systemic application. The JAK1/2 selective JAK inhibitor baricitinib was the first substance from this class of drugs approved by the EMA for the systemic oral treatment of AD. The clinical development program of the JAK1 selective inhibitors upadacitinib and abrocitinib is finalized with positive results for AD. The PAN-JAK inhibitor delgocitinib was the first substance being approved for the treatment of AD (in Japan). This review article covers the rising data on investigational and approved JAK inhibitors in the context of the treatment of AD. Dustri-Verlag Dr. Karl Feistle 2021-08-27 /pmc/articles/PMC8439108/ /pubmed/34532638 http://dx.doi.org/10.5414/ALX02272E Text en © Dustri-Verlag Dr. K. Feistle https://creativecommons.org/licenses/by/2.5/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Traidl, Stephan Freimooser, Sina Werfel, Thomas Janus kinase inhibitors for the therapy of atopic dermatitis |
title | Janus kinase inhibitors for the therapy of atopic dermatitis |
title_full | Janus kinase inhibitors for the therapy of atopic dermatitis |
title_fullStr | Janus kinase inhibitors for the therapy of atopic dermatitis |
title_full_unstemmed | Janus kinase inhibitors for the therapy of atopic dermatitis |
title_short | Janus kinase inhibitors for the therapy of atopic dermatitis |
title_sort | janus kinase inhibitors for the therapy of atopic dermatitis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439108/ https://www.ncbi.nlm.nih.gov/pubmed/34532638 http://dx.doi.org/10.5414/ALX02272E |
work_keys_str_mv | AT traidlstephan januskinaseinhibitorsforthetherapyofatopicdermatitis AT freimoosersina januskinaseinhibitorsforthetherapyofatopicdermatitis AT werfelthomas januskinaseinhibitorsforthetherapyofatopicdermatitis |